Tardive dyskinesia (TD) is a movement disorder. It’s a side effect of taking neuroleptic drugs. Treatment is focused on stopping the recurrence or persistence of symptoms. Tardive dyskinesia (TD) is a ...

Currently there are two FDA approved treatment options for tardive dyskinesia. There are two medications that are VMAT2 inhibitors. These are valbenazine (Ingrezza) and deutetrabenazine (Austedo) made ...

Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced the initiation of its Phase 2 clinical study of investigational compound NBI-1065890 in adults with tardive dyskinesia (TD). NBI-1065890 is ...

Study reveals over half of long-term care residents with tardive dyskinesia do not receive standard treatment, highlighting care gaps. Less than half of patients diagnosed with tardive dyskinesia in ...

Tardive Dyskinesia TD as a neurological disorder resulting in involuntary repetitive movement disorder as a disease of brain Neurology due to dopamine problems. What have studies said the role vitamin ...

Editor’s note: This is a previously posted video, and the below is an automatically generated transcript to be used for informational purposes. Please notify [email protected] if there are concerns ...

(RTTNews) - Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (TEVA), announced results from a study of treatment patterns among patients with tardive dyskinesia (TD) ...

SAN DIEGO, March 20, 2025 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NBIX) (Nasdaq: NBIX) today presented new data from the long-term, open-label KINECT ® 4 study demonstrating remission of tardive ...

Researchers developed a standardized tool to assess the functional impact of tardive dyskinesia on patients. A standardized scale to assess the severity of symptoms in patients with tardive dyskinesia ...

Differentiating tardive dyskinesia from other movement disorders can be challenging. "One major criterion is the history of exposure to neuroleptic medications," said Jeff Bronstein, MD, PhD, of the ...

TEL AVIV, Israel and PARSIPPANY, N.J., Nov. 01, 2024 (GLOBE NEWSWIRE) -- Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (TEVA), today announced new patient- and ...